BRCA pathogenic variants and response in early TNBC patients treated with neoadjuvant pembrolizumab: outcomes of the BRCAPATH study.

Fiche publication

Date publication

juin 2026

Journal

Breast cancer (Tokyo, Japan)

Auteurs

Membres identifiés du Cancéropôle Est :
Dr LIMACHER Jean-Marc

Tous les auteurs :
Popescu BV, Simon L, Blaye C, Marchi S, Flèche A, Gau S, Guermazi F, Stancu A, Mery B, Limacher JM, Dobi E, Leheurteur M

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/42301385

Résumé

Current data on BRCA status and response to neoadjuvant pembrolizumab plus chemotherapy are limited. This study evaluated the association between BRCA status and pathological complete response (pCR) in patients with early triple-negative breast cancer (TNBC).